Article Details

Bharat Biotech seeks DCGI nod for phase-3 study of intranasal Covid vaccine in 5-18 age group

Retrieved on: 2022-09-11 11:27:11

Tags for this article:

Click the tags to see associated articles and topics

Bharat Biotech seeks DCGI nod for phase-3 study of intranasal Covid vaccine in 5-18 age group. View article details on hiswai:

Excerpt

iNCOVACC is a recombinant replication deficient adenovirus vectored vaccine with a pre-fusion stabilised spike protein. This vaccine candidate was ...

Article found on: economictimes.indiatimes.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up